An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients With Gastric Cancer
National Cancer Center Hospital East
National Cancer Center Hospital East
Astellas Pharma Inc
Amgen
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
ImmunityBio, Inc.
National Cancer Institute (NCI)
Sichuan Baili Pharmaceutical Co., Ltd.
AstraZeneca
University of Southern California
Tesaro, Inc.
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
The Netherlands Cancer Institute
OncoC4, Inc.
Hummingbird Bioscience
Australasian Gastro-Intestinal Trials Group
University Hospital Schleswig-Holstein
The Netherlands Cancer Institute